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ABSTRACT 
Objectives: We sought to evaluate the patterns of use and outcomes associated with eptifibatide and 
abciximab administration among dialysis patients who underwent PCI. 
Background: Contraindicated medications are frequently administered to dialysis patients undergoing 
PCI often resulting in adverse outcomes. Eptifibatide is a glycoprotein IIb/IIIa inhibitor that is often 
used during PCI and is contraindicated in dialysis. 
Methods: We included dialysis patients who underwent PCI from 1/2010 - 9/2015 at 47 hospitals in 
Michigan. We compared outcomes between patients who received eptifibatide compared with abcixi-
mab. Both groups required concurrent treatment with unfractionated heparin only. In-hospital outcomes 
included repeat PCI, bleeding, major bleeding, need for transfusion, and death. Optimal full matching 
was used to adjust for non-random drug administration. 
Results: Of 177,963 patients who underwent PCI, 4,303 (2.4%) were on dialysis. Among those, 384 
(8.9%) received eptifibatide and 100 (2.3%) received abciximab. Prior to matching, patients who re-
ceived eptifibatide had higher pre-procedural hemoglobin levels (11.3 g/dL vs. 10.7 g/dL; P < 0.001) 
and less frequently had a history of myocardial infarction (36.5% vs. 52.0%; P = 0.005). After matching, 
there were no significant differences in in-hospital outcomes between eptifibatide and abciximab includ-
ing transfusion (aOR: 1.15; 95% CI: 0.55–2.40; P=0.70), bleeding (1.47; 0.64–3.40; P=0.36), major 
bleeding (4.68; 0.42–52.3; P=0.21), repeat PCI (0.38; 0.03–4.23; P=0.43), and death (1.53; 0.2 –9.05; 
P=0.64). 
Conclusions: Despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times 
more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar 
in-hospital outcomes. 
Keywords: glycoprotein inhibitors; outcomes; bleeding; transfusion; PCI; dialysis 
ABBREVIATIONS 
PCI = percutaneous coronary intervention 
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GPI = glycoprotein IIb/IIIa inhibitor 
UFH = unfractionated heparin 
BMC2 = Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
NCDR = National Cardiovascular Data Registry 
CAD = coronary artery disease 
STEMI = ST-segment elevation myocardial infarction 
NSTEMI = non-ST-segment elevation myocardial infarction 
IABP = intra-aortic balloon pump 
ASD = absolute standardized difference 
aOR = adjusted odds ratio 
TIMI = Thrombolysis in Myocardial Infarction 
 
 
 
 
 
Introduction 
 Due to the high prevalence of cardiovascular disease among patients with kidney disease,1 this 
population frequently undergoes cardiovascular procedures such as percutaneous coronary intervention 
(PCI) where they are at an increased risk of post-procedural bleeding and death compared with patients 
without kidney disease.2-6 Paradoxically, patients on dialysis are also at an increased risk of thrombosis.7 
Therefore, research devoted to defining the optimal antithrombotic regimen during PCI in this 
population is needed. Unfortunately, due to the under-representation or exclusion of patients with kidney 
disease from cardiovascular randomized clinical trials,8 there remains a remarkable dearth of evidence 
guiding treatment in this population.  
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Further complicating this issue is the fact that many medications are metabolized and excreted by 
the kidney, thereby placing these patients at risk of receiving contraindicated medications.9-11 One such 
drug is eptifibatide – a glycoprotein IIb/IIIa inhibitor (GPI) that has been shown to reduce ischemic 
complications during and after PCI.12, 13 Per the manufacturer’s labeling, eptifibatide is contraindicated 
in dialysis as its “safety and efficacy” has not been established in these patients.14 In a landmark paper 
by Tsai et al., the authors demonstrated that nearly a quarter of dialysis patients undergoing PCI 
received eptifibatide or low molecular weight heparin, two contraindicated medications in dialysis. 
Furthermore, they found that administration of contraindicated medications was associated with an 
increased risk of in-hospital major bleeding.9  
Due to this important and alarming statistic, most would agree that efforts should be made to 
reduce the use of contraindicated medications during PCI in patients on dialysis. As such, we sought to 
evaluate the contemporary use of eptifibatide in dialysis patients undergoing PCI, and to assess the 
comparative safety of eptifibatide compared with abciximab in these patients using a multicenter registry 
in the state of Michigan.  
 
Methods 
 
Study population 
We performed a retrospective analysis on data from the Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium (BMC2), a quality improvement group and regional registry of all patients 
undergoing PCI in the state of Michigan. A more detailed description of the registry, including data col-
lection and auditing practices, has been described previously.15, 16 This is a prospective, multicenter, 
statewide registry of patients undergoing PCI at all non-federal hospitals in Michigan. For the current 
study, consecutive patients undergoing PCI between January 2010 and September 2015 at 47 hospitals 
were included. 
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Study Groups 
We divided patients into two groups by the use of renal dialysis. Patients were considered to re-
quire dialysis if they were “undergoing either hemodialysis or peritoneal dialysis on an ongoing basis as 
a result of renal failure” prior to PCI.17 To compare the safety of abciximab and eptifibatide, we strati-
fied dialysis patients by these two drugs. Next, we excluded patients who received a GPI with any anti-
coagulant other than unfractionated heparin (UFH) to reduce bias associated with differential anticoagu-
lant administration. Patients receiving low molecular weight heparin or fondaparinux were excluded be-
cause low molecular weight heparin is contraindicated in dialysis and fondaparinux is rarely used during 
PCI. We excluded patients who received bivalirudin and a GPI because GPIs are frequently adminis-
tered with bivalirudin as a “bailout” strategy for the treatment of suboptimal procedural results or com-
plications, thereby representing a high-risk subgroup of patients.18 Finally, patients who underwent PCI 
without recorded femoral or radial access were also excluded. 
 
Clinical outcomes 
 All outcomes were measured during the incident hospitalization when PCI was performed. In-
hospital outcomes included the need for transfusion, bleeding, presumed major bleeding, repeat PCI, and 
mortality due to any cause. The need for transfusion was defined as the receipt of ≥1 unit of red blood 
cell or whole blood transfusion after PCI. Bleeding, as defined by the National Cardiovascular Data 
Registry (NCDR), included an event within 72 hours of PCI that was associated with any of the follow-
ing: a drop in hemoglobin ≥3 g/dL; transfusion of whole blood or packed red blood cells; an intervention 
or surgery at the site of bleeding to reverse, stop, or correct the bleeding.17 Presumed major bleeding was 
defined as a reduction in the patient’s pre-procedural hemoglobin value by >5 g/dL. Repeat PCI was de-
fined as repeat intervention during the incident hospitalization on the lesion that was initially treated. 
 
Statistical analysis 
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Propensity scores were estimated using logistic regression models adjusting for baseline demographic 
and patient clinical variables (supplemental table 1). Using optimal full matching methods, we created 
matched patient strata of patients who were generally similar in terms of baseline characteristics. These 
strata contained varying numbers of patients with (cases) and without (controls) the covariate of interest 
(abciximab or eptifibatide).19 Optimal full matching allows treatment group members to share control 
group members resulting in the use of many more subjects than would be the case if pairwise or 
“greedy” matching were used.19 We required exact matching on race (white vs. non-white), coronary 
artery disease (CAD) presentation (ST-segment elevation myocardial infarction [STEMI], non-ST-
segment elevation myocardial infarction [NSTEMI], unstable angina, stable angina, or other), cardiogen-
ic shock within 24 hours prior to or at the start of PCI, prior coronary artery bypass grafting, pre-
procedural cardiac arrest, and use of an intra-aortic balloon pump (IABP) or other mechanical ventricu-
lar support devices. Absolute standardized differences (ASDs) were estimated for each variable and a 
10% threshold for ASD was used as an indicator of residual imbalance. We then used conditional lo-
gistic regression models accounting for these matched patient strata to assess for independent associa-
tions between procedural GPI administration and in-hospital outcomes.  
Baseline characteristics were reported as means for continuous variables and proportions for cat-
egorical variables. Differences between groups were compared using Fisher’s exact testing for categori-
cal variables and Student t tests for continuous variables. All analyses were performed using R version 
3.2.1.20 
 
Results 
 Between January 2010 and September 2015, a total of 177,963 PCIs were performed at 47 hospi-
tals throughout Michigan. Among those, 4,303 (2.4%) were performed in patients on dialysis. The base-
line characteristics of patients stratified by dialysis use are demonstrated in Table 1. Patients on dialysis 
had more comorbid conditions and experienced significantly worse outcomes after PCI, including in-
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creased rates of blood transfusions (11.9% vs. 2.7%; P < 0.001), bleeding (4.4% vs. 2.8%; P <0.001), 
and death (3.5% vs. 1.5%; P <0.001). Notably, patients on dialysis less frequently experienced major 
bleeding compared with patients not on dialysis (0.6% vs. 1.2%; P <0.001). The most frequent site of 
arterial access in dialysis patients was the femoral artery (90.3%).  
 Of the 4,303 patients on dialysis who underwent PCI, 113 received abciximab and 456 received 
eptifibatide. Of those, a total of 13 (11.5%) patients in the abciximab group and 72 (15.8%) patients in 
the eptifibatide group met at least one exclusion criteria (Figure 1), leaving 100 and 384 patients in the 
abciximab and eptifibatide groups, respectively. Patients who received eptifibatide were more frequently 
white (66.7% vs. 45.0%; P <0.001); had higher pre-procedural hemoglobin levels (11.3 g/dL vs. 10.7 
g/dL; P <0.001); and less frequently had a history of myocardial infarction (36.5% vs. 52.0%; P=0.005) 
(Table 2). Prior to matching, there were no significant differences among in-hospital outcomes between 
patients treated with eptifibatide compared with abciximab: need for transfusion (18.8% vs. 18.0%; 
P=0.86), bleeding (10.2% vs. 10.0%; P=0.96), major bleeding (1.3% vs. 2.0%; P=0.60), repeat PCI 
(1.3% vs. 1.0%; P=0.81), and death (4.4% vs. 8.0%; P=0.15). 
  
Outcomes 
After optimal full matching, the ASDs were <10% for most matched variables (Figure 2) indicat-
ing globally similar baseline characteristics within matched strata (Table 2). Of note, the pre-procedural 
rate of clopidogrel, prasugrel, and ticagrelor administration was 79.2%, 8.9%, and 4.0% for patients re-
ceiving eptifibatide and 74.5%, 6.4%, and 3.3% for patients receiving abciximab, respectively (Table 2). 
There were no significant differences in the adjusted rates and odds of in-hospital outcomes between pa-
tients receiving eptifibatide compared with abciximab, respectively: need for transfusion (14.5% vs. 
16.4%; aOR: 1.15; 95% CI: 0.55 – 2.40; P=0.70), bleeding (8.8% vs. 12.5%; aOR: 1.47; 95% CI: 0.64 – 
3.40; P=0.36), major bleeding (0.3% vs. 1.7%; aOR: 4.68; 95% CI: 0.42 – 52.3; P=0.21), repeat PCI 
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(1.9% vs. 0.6%; aOR: 0.38; 95% CI: 0.03 – 4.23; P=0.43), and death (1.3% vs. 2.2%; aOR: 1.53; 95% 
CI: 0.26 – 9.05; P=0.64) (Figure 3).  
Of the 384 patients who received eptifibatide, 224 (58.3%) received the medication post-
procedurally as well as intra-procedurally whereas the remainder only received it intra-procedurally. In 
an unadjusted analysis, of the 224 patients who received eptifibatide in the intra- and post-procedural 
period 13 (5.8%) patients died, whereas only 4 of the 140 patients (2.5%) who received eptifibatide only 
during the procedure died during the hospitalization. Among the patients treated with abciximab, there 
were 4 deaths among patients treated with abciximab intra-procedurally and post-procedurally (n/N = 
4/61; 6.6%), and 4 deaths among patients treated with abciximab only during the procedure (n/N = 4/39; 
10.2%). The small number of patients in each group limited our ability to further investigate the effect of 
post-procedural GPI administration on outcomes.  
 
Discussion 
 
 Using a large regional registry of patients undergoing PCI, we evaluated the safety of two com-
monly used GPIs, abciximab and eptifibatide, in dialysis patients undergoing PCI. Our study has three 
major findings. First, despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 
times more often than abciximab. Second, after propensity matching there were no significant differ-
ences in important in-hospital outcomes between the two drugs. Third, the frequency of GPI administra-
tion among dialysis patients was generally low; however, the rates of bleeding in this select population 
were high. 
 The use of GPIs around the time of PCI has been shown to reduce ischemic complications when 
added to UFH, although often at the expense of increased bleeding complications.13, 21, 22 Therefore, clin-
ical practice guidelines recommend carefully considering GPI administration in populations at a high 
risk of bleeding events, like patients with kidney disease.18 Nevertheless, in a landmark paper, Tsai et al. 
discovered that nearly a quarter of patients on dialysis undergoing PCI were treated with a contraindicat-
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ed medication such as eptifibatide.9 Despite this highly publicized and alarming statistic, we found that 
eptifibatide continues to be the most frequently prescribed GPI among dialysis patients undergoing PCI.  
The reasons why eptifibatide continues to be used when contraindicated in dialysis remains un-
clear, though we speculate that many factors may play a role. First, eptifibatide is less expensive than 
abciximab which may potentially drive the increased utilization of eptifibatide.23 Furthermore, eptifiba-
tide may be more readily available for emergent administration in the catheterization lab. Second, physi-
cians may not be aware of the contraindications to eptifibatide. If this is the case, clinically useful elec-
tronic medical records should play an important role in reducing this type of error. 
The benefit of GPIs in the management of coronary artery disease was demonstrated through a 
series of large randomized controlled trials which found a 33% reduction in the risk of death, nonfatal 
MI, or urgent revascularization at 30 days among patients undergoing PCI.24 These initial trials primari-
ly compared GPIs to placebo. There has been only one trial directly comparing two GPIs head-to-head. 
The TARGET trial was a multicenter evaluation of tirofiban versus abciximab among patients undergo-
ing PCI with the intent to perform stenting.25 The primary endpoint was a composite of death, nonfatal 
MI, or urgent target-vessel revascularization at 30 days. The investigators discovered a higher rate of the 
primary endpoint among patients treated with tirofiban compared with abxicimab (7.6% vs. 6.0%; haz-
ard ratio = 1.26; 95% CI: 1.01 – 1.57; P=0.038). However, there was a higher rate of Thrombolysis in 
Myocardial Infarction (TIMI) minor bleeding among patients treated with abciximab compared with 
tirofiban (4.3% vs. 2.8%; P<0.001), thus demonstrating the careful balance between ischemic and bleed-
ing complications with these drugs.25 The current study also demonstrates the balance between these two 
complications. Patients treated with eptifibatide had lower adjusted rates of bleeding complications but a 
higher rate of repeat PCI (i.e. ischemic complication) compared with abciximab; however, these differ-
ences were not statistically significant. To date, there have been no trials directly comparing eptifibatide 
with either abciximab or tirofiban. 
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Although we were unable to determine the reasons for the continued use of eptifibatide in this 
high-risk population, it is important to note that we did not find significant differences in the rates of in-
hospital bleeding, transfusion, or mortality among dialysis patients who received eptifibatide compared 
with abciximab.9, 10 A similar finding was noted in a recent study by Barnes et al. where they found no 
significant differences in the rates of peri-procedural bleeding and 30-day mortality among dialysis pa-
tients who received eptifibatide during PCI at a Veterans Affairs hospital, although the confidence inter-
vals around the point estimates were wide.10 Also of note, although Tsai et al. demonstrated an increased 
risk of bleeding among dialysis patients who were treated with a contraindicated medication, eptifibatide 
use was associated with a significantly increased risk of in-hospital bleeding only in the subgroup of pa-
tients presenting with ACS.9 In an unadjusted analysis, we discovered a higher frequency of in-hospital 
death among patients who were treated with eptifibatide in the intra-procedural and post-procedural time 
periods compared with patients who only received intra-procedural eptifibatide. It is possible that con-
tinued eptifibatide treatment after the procedure may result in accumulation of the drug in dialysis pa-
tients leading to a higher rate of adverse events. Of course, such a finding is confounded by the fact that 
procedural complications or other patient characteristics may be associated with post-procedural GPI 
use. Due to the limited number of patients in our study, we did not perform any subgroup analyses out of 
concern for type I errors resulting from multiple testing.  
 
 Limitations  
 There are several important limitations that deserve specific mention. First, as previously noted, 
we were unable to determine the rationale for GPI administration which may have resulted in inadequate 
matching. For example, a modest proportion of patients may have received eptifibatide in a provisional 
fashion due to unmeasured circumstances that occurred during PCI (i.e. extreme thrombus burden, ongo-
ing ischemia, etc.). These factors may represent confounding variables associated with the non-random 
administration of these drugs. Although we attempted to account for the non-random administration of 
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the studied medications through propensity-matching techniques, due to the retrospective nature of this 
study, we were unable to account for all potential confounders. Second, wide confidence intervals 
around the point estimates for the adjusted odds ratios for each outcome may be related to our small 
sample size and limited power to detect a true association. Nevertheless, the direction of the point esti-
mates suggests increased harm with abciximab, not eptifibatide. Third, all hospitals participating in this 
registry are actively engaged in statewide collaborative quality improvement initiatives. As such, these 
findings may not be generalizable to hospitals that do not participate in such initiatives.26 Lastly, we did 
not collect data on medication dosages or the timing of medication administration relative to the pa-
tient’s subsequent dialysis session. This may have an important impact on the safety and efficacy of 
these drugs as prior research has demonstrated that medications are frequently dosed incorrectly in pa-
tients with renal insufficiency.2, 11, 27 Furthermore, prior research suggests that hemodialysis can effec-
tively reverse the antithrombotic effects of eptifibatide, potentially affecting the decision to use the drug 
and its impact on clinical outcomes.14, 28, 29 
 
Conclusion 
 Although eptifibatide is contraindicated in patients on dialysis, it was used approximately 3.5 
times more often than abciximab during PCI. However, in a propensity-matched analysis, we discovered 
similar safety outcomes between eptifibatide and abciximab among dialysis patients who underwent 
PCI. These findings suggest the need for further investigation into the reasons why eptifibatide continues 
to be used in this population and why there are no significant differences in outcomes.  
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FIGURE LEGENDS: 
Figure 1: Study flow diagram 
Figure 2: Plot of absolute standardized differences before and after matching. 
Absolute standardized differences before and after matching in dialysis patients receiving eptifibatide 
compared to abciximab.  
Abbreviations: CABG=coronary artery bypass grafting; CAD=coronary artery disease; 
CVD=cerebrovascular disease; HF=heart failure; LVEF = left ventricular ejection fraction; 
MI=myocardial infarction; PAD=peripheral artery disease; PCI=percutaneous coronary intervention; 
STEMI=ST-segment elevation myocardial infarction; Sx=symptoms. 
 
Figure 3: Adjusted event rates of in-hospital outcomes in the matched cohort 
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Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients receiving 
eptifibatide compared with abciximab. All comparisons are non-significant (P >0.2 for all). 
Abbreviations: PCI=percutaneous coronary intervention. 
 
 
 
 
 
 
 
Table 1: Baseline characteristics and outcomes of patients by dialysis use. 
 
Variable 
On dialysis 
(n=4,303) 
Not on dialysis 
(n=173,660) P value 
Demographics    
 Age (years) 65.23 ± 11.37 65.06 ± 12.04 0.35 
 Male gender 2,573/4,303 (59.8%) 115,853/173,658 (66.7%) < 0.001 
 Body mass index (kg/m2) 30.17 ± 8.73 30.62 ± 7.53 < 0.001 
 White race 2,708/4,303 (62.9%) 150,543/173,660 (86.7%) < 0.001 
 Black or African American race 1,460/4,303 (33.9%) 18,375/173,660 (10.6%) < 0.001 
    
Comorbidities    
 Current/recent smoker (within 1 
year) 837/4,299 (19.5%) 51,038/173,579 (29.4%) < 0.001 
 Hypertension 4,182/4,300 (97.3%) 147,813/173,600 (85.1%) < 0.001 
 Dyslipidemia 3,727/4,294 (86.8%) 142,400/173,505 (82.1%) < 0.001 
 Family history of premature CAD 586/4,301 (13.6%) 31,486/173,606 (18.1%) < 0.001 
 Prior MI 2,086/4,303 (48.5%) 60,363/173,626 (34.8%) < 0.001 
 Prior heart failure 2,301/4,301 (53.5%) 27,032/173,587 (15.6%) < 0.001 
 Prior valve surgery/procedure 131/4,298 (3.0%) 3,022/173,575 (1.7%) < 0.001 
 Prior PCI 2,311/4,303 (53.7%) 78,780/173,629 (45.4%) < 0.001 
 Prior CABG 1,035/4,302 (24.1%) 31,911/173,609 (18.4%) < 0.001 
 Cerebrovascular disease 1,347/4,298 (31.3%) 26,314/173,592 (15.2%) < 0.001 
 Peripheral arterial disease 1,655/4,300 (38.5%) 27,078/173,600 (15.6%) < 0.001 
 Chronic lung disease 1,242/4,299 (28.9%) 32,541/173,593 (18.7%) < 0.001 
 Diabetes mellitus 3,143/4,303 (73.0%) 64,990/173,619 (37.4%) < 0.001 
 Heart failure within 2 Weeks 1,391/4,300 (32.3%) 18,587/173,586 (10.7%) < 0.001 
 Cardiomyopathy or left ventricular 
systolic dysfunction 948/4,302 (22.0%) 17,911/173,618 (10.3%) < 0.001 
 Cardiogenic shock within 24 Hours 127/4,303 (3.0%) 3,069/173,610 (1.8%) < 0.001 
 Cardiac arrest within 24 Hours 84/4,303 (2.0%) 3,370/173,578 (1.9%) 0.96 
 Pre-PCI left ventricular ejection frac-
tion (%) 47.45 ± 14.52 52.03 ± 12.76 < 0.001 
 Pre-procedure hemoglobin (g/dL) 10.76 ± 1.79 13.50 ± 1.88 < 0.001 
     
CAD Presentation    
 No symptom, no angina 336/4,303 (7.8%) 8,805/173,615 (5.1%) < 0.001 
 Symptom unlikely to be ischemic 121/4,303 (2.8%) 4,037/173,615 (2.3%) 0.037 
 Stable angina 412/4,303 (9.6%) 22,827/173,615 (13.1%) < 0.001 
 Unstable angina 1,687/4,303 (39.2%) 73,331/173,615 (42.2%) < 0.001 
 Non-STEMI 1,455/4,303 (33.8%) 36,673/173,615 (21.1%) < 0.001 
 STEMI or equivalent 292/4,303 (6.8%) 27,942/173,615 (16.1%) < 0.001 
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P2Y12 Inhibitor Administration    
 Pre-procedural clopidogrel 1,992/4,303 (46.3%) 61,108/173,660 (35.2%) < 0.001 
 Pre-procedural prasugrel 93/4,303 (2.2%) 6,013/173,660 (3.5%) < 0.001 
 Pre-procedural ticagrelor1 51/2,134 (2.4%) 2,849/81,870 (3.5%) 0.006 
     
Procedural Characteristics    
 Intra-aortic balloon pump 124/4,301 (2.9%) 4,399/173,616 (2.5%) 0.150 
 Other mechanical ventricular support 91/4,298 (2.1%) 1,471/173,586 (0.8%) < 0.001 
 Femoral artery access site 3,838/4,302 (89.2%) 138,287/173,621 (79.6%) < 0.001 
 Radial artery access site 438/4,302 (10.2%) 34,739/173,621 (20.0%) < 0.001 
 Cardiogenic Shock at Start of PCI 133/4,301 (3.1%) 3,578/173,543 (2.1%) < 0.001 
     
PCI Indication    
 Immediate PCI for STEMI 250/4,302 (5.8%) 25,043/173,617 (14.4%) < 0.001 
 PCI for STEMI (Unstable, >12 hours 
from symptom onset) 28/4,302 (0.7%) 1,418/173,617 (0.8%) 0.23 
 PCI for STEMI (Stable, >12 hours 
from symptom onset) 21/4,302 (0.5%) 451/173,617 (0.3%) 0.004 
 PCI for STEMI (Stable after success-
ful full-dose thrombolysis) 1/4,302 (0.0%) 556/173,617 (0.3%) < 0.001 
 Rescue PCI for STEMI (after failed 
full-dose thrombolytics) 4/4,302 (0.1%) 906/173,617 (0.5%) < 0.001 
 PCI for high risk Non-STEMI or 
unstable angina 2,826/4,302 (65.7%) 98,409/173,617 (56.7%) < 0.001 
 Staged PCI 162/4,302 (3.8%) 7,525/173,617 (4.3%) 0.070 
 Other 1,010/4,302 (23.5%) 39,309/173,617 (22.6%) 0.196 
     
In-hospital Outcomes    
 Stent thrombosis 5/4,303 (0.1%) 328/173,660 (0.2%) 0.28 
 Repeat PCI 24/4,303 (0.6%) 724/173,660 (0.4%) 0.158 
 Major bleeding 23/3,911 (0.6%) 1,758/144,904 (1.2%) < 0.001 
 Blood transfusion 510/4,299 (11.9%) 4,745/173,563 (2.7%) < 0.001 
 Bleeding 189/4,299 (4.4%) 4,852/173,560 (2.8%) < 0.001 
 Death 151/4,303 (3.5%) 2,523/173,660 (1.5%) < 0.001 
 
Data are presented as n/N (%) or mean ± standard deviation where appropriate. 
 
1 Data on ticagrelor administration was collected beginning on January 1, 2013. 
 
Abbreviations: CABG=coronary artery bypass grafting; CAD=coronary artery disease; IABP=intra-
aortic balloon pump; MI=myocardial infarction; PCI=percutaneous coronary intervention; 
STEMI=ST-segment elevation myocardial infarction. 
 
 
 
 
 
 
 
 
Table 2: Baseline characteristics of dialysis patients receiving eptifibatide versus abciximab before and 
after matching.  
 
 
    Before matching  After matching 
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Eptifibatide 
(n=384) 
Abciximab 
(n=100) 
Standardized 
difference (%)  P value   
Eptifibatide 
(n=384) 
Abciximab 
(n=100) 
Standardized 
difference (%)  P value 
Demographics          
  Age (years) 64.63 ± 11.73 64.18 ± 11.46 -3.8% 0.73  64.22 64.49 2.3% 0.85 
  Male 55.5% 53.0% 5.0% 0.66  49.0% 53.0% -8.0% 0.57 
  Body mass index (kg/m2) 30.5 30.7 1.6% 0.89  30.1 30.7 5.5% 0.74 
  White race 66.7% 45.0% -45.3% < 0.001  48.8% 48.8% 0.0% >0.99 
  Black or African American race 30.5% 48.0% 37.3% 0.001  47.8% 45.6% -4.6% 0.44 
             
Comorbidities          
  Current/recent smoker (within 1 year) 20.3% 18.0% -5.8% 0.61  19.2% 21.5% 5.7% 0.67 
  Hypertension 95.1% 97.0% 9.3% 0.41  97.9% 96.1% -8.6% 0.42 
  Dyslipidemia 85.4% 81.0% -12.2% 0.28  82.1% 86.7% 12.7% 0.37 
  Family history of premature CAD 15.4% 10.0% -15.3% 0.17  13.2% 11.4% -5.0% 0.69 
  Prior MI 36.5% 52.0% 32.0% 0.005  48.8% 47.9% -2.0% 0.88 
  Prior heart failure 45.3% 52.0% 13.4% 0.23  48.3% 51.1% 5.7% 0.68 
  Prior valve surgery/procedure 1.6% 4.0% 17.1% 0.13  2.2% 4.2% 14.2% 0.39 
  Prior PCI 40.6% 50.0% 19.0% 0.092  44.9% 48.6% 7.3% 0.57 
  Prior CABG 16.1% 25.0% 23.1% 0.040  22.0% 22.0% 0.0% >0.99 
  Cerebrovascular disease 25.0% 29.0% 9.1% 0.42  30.2% 27.5% -6.1% 0.67 
  Peripheral arterial disease 28.1% 35.0% 15.1% 0.18  32.5% 30.7% -4.1% 0.76 
  Chronic lung disease 25.3% 30.0% 10.8% 0.34  29.0% 29.2% 0.5% 0.97 
  Diabetes mellitus 68.2% 73.0% 10.3% 0.36  73.3% 72.9% -1.0% 0.94 
  Heart failure within 2 weeks 26.0% 35.0% 20.0% 0.076  27.5% 31.0% 7.8% 0.56 
  
Cardiomyopathy or left ventricular sys-
tolic dysfunction 17.4% 23.0% 14.3% 0.20  18.3% 22.1% 9.8% 0.45 
  Cardiogenic shock within 24 hours 3.9% 7.0% 14.8% 0.19  1.5% 0.9% -2.9% 0.48 
  Cardiac arrest within 24 hours 2.3% 2.0% -2.3% 0.84  0.0% 0.0% 0.0% >0.99 
  
Pre-PCI left ventricular ejection frac-
tion (%) 48.0 ± 12.9 46.4 ± 13.0 -12.2% 0.28  47.8 47.5 -1.9% 0.87 
  Pre-procedure hemoglobin (g/dL) 11.3 ± 2.1 10.7 ± 1.6 -31.4% < 0.001  11.0 10.8 -8.1% 0.47 
             
CAD Presentation          
  No symptom, no angina 7.3% 4.0% -13.2% 0.24  4.5% 4.5% 0.0% >0.99 
  Symptom unlikely to be ischemic 1.3% 3.0% 13.3% 0.25  1.2% 1.2% 0.0% >0.99 
  Stable angina 9.4% 8.0% -4.8% 0.67  10.1% 10.1% 0.0% >0.99 
  Unstable angina 31.0% 28.0% -6.5% 0.56  30.5% 30.5% 0.0% >0.99 
  Non-STEMI 32.0% 42.0% 21.1% 0.061  40.6% 40.6% 0.0% >0.99 
  STEMI or equivalent 19.0% 15.0% -10.4% 0.36  13.1% 13.1% 0.0% >0.99 
           
Pre- & Intra-procedural Antiplatelet therapy         
 Clopidogrel 75.8% 71.0% -10.8% 0.33  79.2% 74.5% 11.1% 0.42 
 Prasugrel 10.4% 9.0% -4.8% 0.68  8.9% 6.4% 9.5% 0.50 
 Ticagrelor1 4.2% 4.0% -0.8% 0.94  4.0% 3.3% 3.7% 0.80 
 Aspirin 90.6% 97.0% 26.7% 0.037  87.6% 97.8% -39.8% 0.008 
             
Procedural Characteristics          
  IABP 4.2% 6.0% 8.8% 0.43  1.8% 1.8% 0.0% >0.99 
  Other mechanical ventricular support 1.8% 4.0% 14.6% 0.19  1.2% 1.2% 0.0% >0.99 
  Femoral artery access site 88.5% 88.0% -1.7% 0.88  89.1% 86.7% -7.3% 0.58 
  Radial artery access site 11.5% 12.0% 1.7% 0.88  10.9% 13.3% 7.3% 0.58 
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 Cardiogenic shock at start of PCI 4.2% 6.0% 8.8% 0.43  1.2% 2.1% 4.4% 0.32 
             
PCI Indication          
  Immediate PCI for STEMI 17.4% 12.0% -14.7% 0.19  12.7% 12.1% -1.4% 0.67 
  
PCI for STEMI (Unstable, >12 hours 
from symptom onset) 1.3% 0.0% -12.9% 0.25  0.0% 0.0% 0.0% >0.99 
  
PCI for STEMI (Stable, >12 hours from 
symptom onset) 1.0% 2.0% 8.6% 0.44  0.4% 0.9% 4.7% 0.67 
  
PCI for STEMI (Stable after successful 
full-dose thrombolysis) 0.0% 0.0% 0.0% <0.001  0.0% 0.0% 0.0% <0.001 
  
Rescue PCI for STEMI (after failed 
full-dose thrombolytic) 0.0% 1.0% 22.1% 0.050  0.0% 0.0% 0.0% >0.99 
  
PCI for high risk Non-STEMI or unsta-
ble angina 53.9% 65.0% 22.4% 0.047  63.3% 66.5% 6.4% 0.28 
  Staged PCI 0.8% 0.0% -9.9% 0.38  0.0% 0.0% 0.0% >0.99 
  Other 25.5% 20.0% -12.8% 0.25  23.6% 20.4% -7.4% 0.28 
 
Data are presented as percentages (%) or means  standard deviations where appropriate. 
 
1 Data on ticagrelor administration was collected beginning on January 1, 2013. 
 
Abbreviations: CAD=coronary artery disease; MI=myocardial infarction; PCI=percutaneous coronary 
intervention; CABG=coronary artery bypass grafting; STEMI=ST-segment elevation myocardial 
infarction; IABP=intra-aortic balloon pump.  
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Figure 1: Study flow diagram 
 
 
Abbreviations: PCI=percutaneous co onary intervention 
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Figure 2: Plot of absolute standardized differences before and after matching. 
 
 
Absolute standardized differences before and after matching in dialysis patients receiving eptifibatide 
compared with abciximab.  
 
Abbreviations: CABG = coronary artery bypass grafting; CAD = coronary artery disease; CVD = cer-
ebrovascular disease; HF = heart failure; LVEF = left ventricular ejection fraction; MI = myocardial 
infarction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-
segment elevation myocardial infarction; Sx = symptoms. 
 
 
 
 
Figure 3: Adjusted event rates of in-hospital outcomes in the matched cohort 
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Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients receiving 
eptifibatide compared with abciximab. All comparisons are non-significant (P >0.20 for all). 
Abbreviations: PCI=percutaneous coronary intervention 
 
 
 
 
 
 
 
